Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.

被引：0
作者：
Kaseb, Ahmed Omar [1 ]
Pestana, Roberto Carmagnani [1 ]
Vence, Luis M. [1 ]
Blando, Jorge M. [1 ]
Singh, Shalini [1 ]
Ikoma, Naruhiko [1 ]
Vauthey, Jean-Nicolas [1 ]
Allison, James Patrick [1 ]
Sharma, Padmanee [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 08期
关键词：
D O I：
10.1200/JCO.2019.37.8_suppl.52
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
52
引用
收藏
页数：2
相关论文
共 50 条
  • [31] NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
    Vilde Drageset Haakensen
    Anna K. Nowak
    Espen Basmo Ellingsen
    Saima Jamil Farooqi
    Maria Moksnes Bjaanæs
    Henrik Horndalsveen
    Tine Mcculloch
    Oscar Grundberg
    Susana M. Cedres
    Åslaug Helland
    Journal of Translational Medicine, 19
  • [32] Neoadjuvant chemoradiotherapy with ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial.
    Laengle, Johannes
    Kuehrer, Irene
    Kulu, Askin
    Kabiljo, Julijan
    Ammon, Daphni
    Zirnbauer, Rebecca
    Stift, Anton
    Herbst, Friedrich
    Dauser, Bernhard
    Monschein, Matthias
    Razek, Peter
    Biebl, Matthias
    Geinitz, Hans
    Hulla, Wolfgang
    Muellauer, Leonhard
    Widder, Joachim
    Bittermann, Clemens
    Laengle, Friedrich
    Schmid, Rainer
    Bergmann, Michael M.
    CHINOREC Study Grp
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 139 - 139
  • [33] NEOADJUVANT CHEMORADIOTHERAPY WITH SEQUENTIAL IPILIMUMAB AND NIVOLUMAB IN RECTAL CANCER (CHINOREC): A PROSPECTIVE RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II CLINICAL TRIAL
    Laengle, J.
    Kuehrer, I.
    Pils, D.
    Kabiljo, J.
    Woeran, K.
    Stift, J.
    Herbst, F.
    Dauser, B.
    Monschein, M.
    Razek, P.
    Haegele, S.
    Herac, M.
    Hulla, W.
    Bitterman, C.
    Laengle, F.
    Tamandl, D.
    Widder, J.
    Schmid, R.
    Bergmann, M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A51 - A51
  • [34] RANDOMIZED PHASE II OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (RGBM). NIVOLUMAB BENEFITS OLDER POPULATION
    Ahluwalia, Manmeet
    Peereboom, David
    Rauf, Yasmeen
    Wen, Patrick
    Reardon, David
    NEURO-ONCOLOGY, 2021, 23 : 52 - 52
  • [35] RANDOMIZED PHASE II OPEN-LABEL STUDY OF NIVOLUMAB PLUS STANDARD-DOSE BEVACIZUMAB VS NIVOLUMAB PLUS LOW-DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (RGBM): FINAL REPORT
    Ahluwalia, Manmeet
    Khosla, Atulya
    Rauf, Yasmeen
    Peereboom, David
    Wen, Patrick Y.
    Reardon, David A.
    NEURO-ONCOLOGY, 2022, 24 : 64 - 64
  • [36] Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
    Hodi, Frank Stephen
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Grob, Jean-Jacques
    Rutkowski, Piotr
    Cowey, Charles Lance
    Lao, Christopher D.
    Schadendorf, Dirk
    Wagstaff, John
    Dummer, Reinhard
    Ferrucci, Pier Francesco
    Smylie, Michael
    Hill, Andrew
    Hogg, David
    Marquez-Rodas, Ivan
    Jiang, Joel
    Rizzo, Jasmine
    Larkin, James
    Wolchok, Jedd D.
    LANCET ONCOLOGY, 2018, 19 (11) : 1480 - 1492
  • [37] A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated metastatic renal cell carcinoma
    Hammers, H.
    Sternberg, C.
    Mcdermott, D. F.
    Larkin, J.
    Ravaud, A.
    Rini, B.
    Sharma, P.
    Bhagavatheeswaran, P.
    Gagnier, P.
    Motzer, R.
    BJU INTERNATIONAL, 2014, 114 : 9 - 9
  • [38] 1 Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
    Zamarin, Dmitriy
    Burger, Robert A.
    Sill, Michael W.
    Powell, Daniel J., Jr.
    Lankes, Heather A.
    Feldman, Michael D.
    Zivanovic, Oliver
    Gunderson, Camille
    Ko, Emily
    Mathews, Cara
    Sharma, Sudarshan
    Hagemann, Andrea R.
    Khleif, Samir
    Aghajanian, Carol
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1814 - +
  • [39] Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
    Namikawa, Kenjiro
    Kiyohara, Yoshio
    Takenouchi, Tatsuya
    Uhara, Hisashi
    Uchi, Hiroshi
    Yoshikawa, Shusuke
    Takatsuka, Sumiko
    Koga, Hiroshi
    Wada, Naoko
    Minami, Hironobu
    Hatsumichi, Masahiro
    Asada, Suguru
    Namba, Yoshinobu
    Yamazaki, Naoya
    EUROPEAN JOURNAL OF CANCER, 2018, 105 : 114 - 126
  • [40] Phase II study of axitinib intensification compared to nivolumab alone after induction with ipilimumab plus nivolumab in patients with mRCC without previous complete response (AxIn study).
    Ciccarese, Chiara
    Verzoni, Elena
    Bimbatti, Davide
    Buti, Sebastiano
    Calabro, Fabio
    Galli, Luca
    Scagliarini, Sarah
    Fornarini, Giuseppe
    Baldessari, Cinzia
    Bilancia, Domenico
    Facchini, Gaetano
    Cattrini, Carlo
    Masini, Cristina
    Giganti, Maria Olga
    Scandurra, Giuseppa
    Nole, Franco
    Berruti, Alfredo
    Milella, Michele
    Antonuzzo, Lorenzo
    Iacovelli, Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS494 - TPS494
12345